RE: Clinical trial updated14 Apr 2023 10:11
RNS states US are recruiting for 1a:
The opening of the US phase 1 trial sites for recruitment marks a significant milestone in Avacta's plan to expand AVA6000 clinical studies. A phase 1a dose escalation study is currently underway in the UK and recently begun dosing patients in the fifth cohort at 250 mg/m2 as announced on 5 April 2023, following the favourable safety profile of AVA6000 generated in the study to date. The US trial sites will initially contribute patients to the dose escalation phase, while being uniquely positioned to lead the enrolment of soft tissue sarcoma patients in the phase 1b dose expansion stage of the AVA6000 study when this begins. Patients will receive the same doses at each stage of the trial as in the UK.